Welcome to our dedicated page for Fifty 1 Labs news (Ticker: FITY), a resource for investors and traders seeking the latest updates and insights on Fifty 1 Labs stock.
Fifty 1 Labs, Inc. develops biotechnology and life sciences initiatives centered on peptide products, peptide discovery, AI-enabled research, and clinical development for musculoskeletal health, recovery, and performance. News about FITY commonly covers the company’s transition into peptide biotechnology, its use of artificial intelligence in discovery and research, and program areas involving muscle, tendon, ligament, bone, pain management, injury recovery, and personalized wellness.
Company updates also address capital-structure actions, including the retirement of Series B Preferred Stock to reduce potential common-share dilution, as well as governance, audit, and corporate-status developments. Recent corporate communications have clarified the status of former subsidiary relationships and prior collaboration references while keeping the company’s current focus on peptide therapeutics and wellness-oriented life sciences.
Fifty 1 Labs (FITY) has acquired Genetic Networks for $10 million in common shares, appointing Dr. Gennaro D'Urso as CEO and Chairman. The acquisition brings the proprietary GeneScape™ platform, which integrates genomics, AI, and machine learning to accelerate drug discovery.
The GeneScape™ technology analyzes gene-drug interactions across 6,000 genes, reducing traditional drug development timelines from 9-12 years to 2-4 years. The platform offers applications in drug repurposing, biothreat research, and food additive testing.
Genetic Networks is currently negotiating multi-million dollar contracts with the Department of Defense (DoD) for developing biothreat countermeasures. The company plans to expand operations, enhance products, and secure partnerships with pharmaceutical companies.
4Cable TV International (CATV) has announced several strategic developments on March 20, 2025. The company facilitated the acquisition of Genetic Networks by Fifty 1 Labs, Inc. (FITY), which will result in a dividend distribution to CATV shareholders pending FINRA approval.
The company has significantly strengthened its financial position by eliminating $800,000 in debt and reducing 930 million dilutive shares, following a previous reduction of 7.8 billion shares on March 17, 2025. This brings the total share reduction to 8.7 billion shares.
Current Interim CEO Michael Feldenkrais will resign but oversee the transition as the company prepares for a reverse merger with a new company. The merger, expected in the coming weeks, will include a new name, ticker symbol, and management team.
Fifty 1 Labs (OTCPK: FITY), formerly Consumer Automotive Finance (OTCPK: CAFI), has completed its name and ticker symbol change with FINRA, now trading as FITY on the OTC market. The company, operating in the sports supplement, fitness equipment, and health and wellness sectors, has submitted responses to a second round of comments in its effort to regain SEC Rule 15c2-11 compliance.
The company has rescheduled its teleconference to March 17th, 2025, where management will discuss strategic direction and provide updates. CEO Brandon Spikes emphasized the importance of the name change in strengthening their market position and highlighted that regaining 15c2-11 compliance remains a priority for improving shareholder transparency and liquidity.